Bispecific EGFRvIII x CD3 antibody engaging molecules

US9249217B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, DHHS · US
• Duke University · US

Inventors

• Darell Bigner · Mebane, US
• Chien-Tsun Kuan · Cary, US
• John H. Sampson · Durham, US
• Mingqing Cai · Durham, US
• Bryan Choi · Boston, US
• Ira H. Pastan · Potomac, US

Key dates

• Filing date: Nov 15, 2011
• Grant date: Feb 2, 2016
• Expiry date: Nov 15, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific.